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Michelangelo, the Sistine Chapel  
and the “secret” of cancer cachexia
Introduction
When visiting Rome, the Vatican and its museums are a “must 
see”. Thousands of tourists visit the Sistine Chapel and admire the 
famous frescos by Michelangelo decorating the ceiling. Many are 
overwhelmed by the beauties of the scenes depicted. Others are 
more concerned on how Michelangelo could have painted these 
masterpieces lying on his back. But very few, when looking at the 
“Creation of Adam”, realise that Michelangelo was hiding a message 
in that scene, which is now becoming scientific evidence after 
500 years.
In cancer patients, a progressive and apparently unstoppable 
deterioration of nutritional status frequently occurs, leading to 
worsened clinical outcome.1 Accumulating evidence indicates 
that this multifaceted syndrome is the clinical manifestation of a 
persistent, yet moderate inflammatory response, induced by the 
growing tumour. Although a number of symptoms contribute to 
the onset of severe malnutrition in cancer patients, anorexia (i.e. 
reduced appetite and energy intake) and peripheral tissue wasting, 
which is traditionally referred to as cachexia, are the leading 
causative factors.1 Therefore, the term anorexia-cachexia syndrome 
has been largely used to define the cancer-associated nutritional 
deterioration. More recently, however, the better knowledge of the 
molecular mechanisms of anorexia and tissue wasting revealed that 
a number of pathogenic pathways are shared by these two clinical 
conditions. In particular, the activity of specialised hypothalamic 
areas modulating energy homeostasis appears to be involved in 
mediating the behavioural and nutritional complications associated 
with cancer. Consequently, the term “cancer cachexia” is now 
becoming more frequently used in the clinical setting to define the 
progressive deterioration of nutritional status of cancer patients, 
irrespective of the relative contribution of anorexia and metabolic 
changes.
Cancer anorexia
The pathological and persistent loss of appetite, i.e. anorexia, is 
a clinically relevant symptom since it is highly prevalent and is a 
robust predictor of increased risk of death in hospitalised patients,2 
particularly in cancer patients.3 Also, anorexia impinges on the 
quality of life, and is a key determinant of cancer patients’ quality 
of life.4
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Uncertainties still exist in clearly defining and diagnosing anorexia.5 
In order to provide a diagnostic tool allowing a qualitative and 
quantitative assessment of cancer anorexia, the European Society 
for Clinical Nutrition and Metabolism (ESPEN) has recently developed 
an Anorexia Questionnaire, adapted from the AC/S-12 of Functional 
Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire.6 
This diagnostic tool includes 12 questions related to appetite and 
eating behaviour, whose multiple answers are anchored to a score. 
A total score ≤ 24 has been proposed as being sufficient to make 
diagnosis of anorexia.6
Pathogenesis of anorexia and reduced energy intake
Regulation of food intake. Under physiological conditions, the 
homeostasis of food intake is controlled by complex and redundant 
mechanisms.7 Neural, metabolic, and humoral signals from 
peripheral tissues inform the brain whether energy stores are being 
repleted or depleted. The hypothalamus receives and integrates 
peripheral signals. Within the hypothalamus, the infundibular nucleus 
in humans (i.e. the arcuate nucleus in rodents), is considered to act 
as an important sensor of alterations in energy stores to control 
appetite and body weight. Involved in this role are two distinct 
subsets of neurons.
The first population of neurons express pro-opiomelanocortin 
(POMC). POMC is an inert polypeptide precursor which is cleaved 
into the biologically active melanocortins, i.e. α-, β-, γ-melanocyte-
stimulating hormone (MSH). The biological effects of melanocortins 
are mediated through a family of five melanocortin receptors, 
termed MC1R to MC5R. Among them, MC4R is a crucial molecular 
component of the homoeostatic circuit that regulates energy balance 
by mediating anorectic and catabolic responses.
The second subset of neurons expresses the potent orexigenic 
peptides neuropeptide Y (NPY) and agouti-related protein (AgRP). 
Interestingly, AgRP is the endogenous antagonist of MC4Rs, 
thereby antagonising the anorexigenic effects of melanocortins. 
This evidence underlines the reciprocal functional relationship 
between the two subsets of hypothalamic neurons. The POMC 
and NPY/AgRP neurons project to related hypothalamic nuclei, and 
these downstream second-order neurons expressing melanocortin 
receptors are included in the hypothalamic melanocortin system.
The melanocortin system plays a crucial role in the homeostasis 
of energy metabolism. In the presence of excess energy, POMC 
neurons are activated and trigger the release of melanocortins, 
which activate MC4R thereby leading to suppressed food intake and 
increased energy expenditure. Simultaneously, the activity of arcuate 
AgRP/NPY system is suppressed, which would otherwise antagonise 
the effects of melanocortins on MC4R. In contrast, in times of energy 
depletion, the activity of anorexigenic POMC neurons is decreased 
but the activity of orexigenic NPY/AgRP neurons is increased.
Peripheral factors and cancer anorexia. Under physiological 
conditions, the hypothalamus integrates a number of peripheral 
inputs and modulates eating behaviour accordingly. These signals 
arise from peripheral tissues, mainly from the gastrointestinal tract, 
and are conveyed to the hypothalamus.8 The biological functions 
of these signals are different and time-specific. Consequently, 
peripheral signals are usually classified as short-term (i.e. visual-
oro-nasal stimuli, ghrelin, cholecystokinin), medium-term (i.e. rising 
concentrations in plasma of specific nutrients, polypeptide YY) and 
long-term (i.e. leptin, insulin) signals.
Considering the role of peripheral signals in mediating the onset 
of appetite and satiety, it was tempting to speculate that changes 
in peripheral signals could mediate the development of cancer 
anorexia. However, consistent experimental data suggest that 
cancer anorexia mainly results from the resistance of hypothalamic 
neurons to peripheral signals.
Brain neurochemistry and cancer anorexia. The hypothalamic 
inappropriate response to these peripheral signals appears to be 
mediated by the persistent activation of POMC neurons.9 Consistent 
evidence indicates that MC4Rs are key factor in mediating anorexia 
and body weight loss during cancer.10 Furthermore, experimental 
data suggest that decreased activity of NPY/AgRP neurons should 
parallel the hyperactivation of POMC neurons in the presence of 
cancer. Immuncytochemical studies in tumour-bearing rats with 
anorexia-cachexia show decreased NPY innervation of hypothalamic 
nuclei, which is reversed by tumour resection.11 Direct measurement 
of NPY concentrations in the hypothalamus of tumour-bearing 
rats with anorexia-cachexia reveals a significant decrease of this 
orexigenic peptide. In humans, data on hypothalamic NPY levels 
and activity during cancer are lacking. However, significantly lower 
plasma levels of NPY have been measured in anorectic cancer 
patients when compared to controls. Furthermore, animal studies 
show that megestrol acetate, an orexigenic drug used in the 
treatment of human cachexia, increases hypothalamic NPY levels.
The mechanisms responsible for the dysfunction of the melanocortin 
system have been investigated in experimental studies, and results 
suggest the involvement of pro-inflammatory cytokines and the 
neurotransmitter serotonin.12,13 The role of pro-inflammatory 
cytokines, and particularly IL-1, IL-6 and TNF-α, in the pathogenesis 
of cancer anorexia has been recognised for many years. In tumour-
bearing rats with anorexia, hypothalamic IL-1 mRNA expression is 
significantly increased. In humans, IL-1 appears to play a significant 
role in mediating anorexia since megestrol acetate has been shown 
to improve appetite and food intake via reduced expression of IL-1 
by mononuclear cells, which may explain its effects on hypothalamic 
NPY concentrations. Interestingly, POMC neurons express the type I 
IL-1 receptor, and intracerebroventricular injection of IL-1 increases 
the frequency of action potentials of POMC neurons and stimulates 
the release of α-MSH. These data strongly suggest that IL-1 is 
involved in mediating the dysfunction of the melanocortin system by 
increasing the activity of POMC neurons in the hypothalamus.
Serotonin is a neurotransmitter that contributes to the regulation 
of energy balance, by mediating satiety through its effects in the 
hypothalamus.13 In experimental tumour models, the onset of 
anorexia is associated with increased hypothalamic serotonin levels, 
as assessed by in vivo microdialysis, and increased expression of 
serotonin receptors (5-HTRs). Also, tumour resection restores energy 
intake, which is associated to normalised hypothalamic serotonin 
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concentrations and receptor expression. In cancer patients, the role 
of serotonin in cancer anorexia has been inferred by measuring 
increased plasma and cerebrospinal fluid levels of the precursor of 
serotonin, the amino acid tryptophan, in anorectic cancer patients. 
Intriguingly, the anorectic effects of serotonin appear to be mediated 
by the melanocortin system.
These data indicate that during cancer, increased hypothalamic 
expression of IL-1 occurs in conjunction with increased release of 
serotonin. Serotonin and IL-1 interact within the arcuate nucleus 
(infundibular nucleus in humans) to influence the activity of the 
melanocortin system, yielding and maintaining the inhibition of 
NPY/AgRP neuronal activity. These biochemical events facilitate the 
release of the endogenous MC4R agonist, α-MSH, while suppressing 
the release of the endogenous MC4R antagonist, AgRP, thus resulting 
in dysfunction of the melanocortin system.
Hypothalamic energy metabolism and cancer anorexia. The 
hypothalamic regulation of food intake involves different pathways. 
Indeed, fatty acid metabolism within hypothalamic neurons controls 
food intake and energy metabolism in a leptin-independent 
way.12 In particular, inhibition of fatty acid synthase (FAS) blocks 
fasting-induced upregulation of orexigenic neuropeptides and 
downregulation of anorexigenic neuropeptides. Hypothalamic 
malonyl-coenzyme A (CoA), a substrate of FAS, is an indicator of 
global energy status. Its concentration is low in fasted mice and 
rapidly increases on refeeding. Therefore, high intrahypothalamic 
malonyl-CoA induces anorexia by inhibiting fatty acid oxidation, 
whereas low levels have the converse effect and elicit food intake.
The FAS/malonyl-CoA pathway could be involved in the pathogenesis 
of cancer anorexia, because in-vitro studies show that pro-
inflammatory cytokines, particularly TNF-α and IL-1, inhibit fatty 
acid oxidation. If this effect also applies to the in-vivo situation, 
then pro-inflammatory cytokines, and particularly IL-1, may cause 
an inappropriate switch in hypothalamic neurons from fatty acid 
oxidation to fatty acid synthesis, increase hypothalamic malonyl-CoA 
concentrations and suppress food intake.
Cancer cachexia
Changes in intermediary metabolism largely contribute to wasting 
and mediate a number of clinically relevant symptoms and signs 
in cancer patients. Robust experimental and clinical data indicate 
that chronic inflammation, as already discussed for the pathogenesis 
of cancer anorexia, represents the main trigger of the changes in 
intermediary metabolism.
Pathogenesis of wasting 
Protein metabolism in cancer patients. Under physiological 
conditions, protein degradation in muscle is offset by compensatory 
protein synthesis to preserve muscle mass. During cancer, muscle 
catabolic pathways are hyperactivated, while a compensatory 
increase of muscle anabolism does not occur. The net result is the 
progressive loss of muscle mass and muscle function. There are 
three main proteolytic pathways that are responsible for protein 
catabolism in skeletal muscle.14 The first pathway is the lysosomal 
system, which is involved in proteolysis of extracellular proteins 
and cell-surface receptors. The second pathway is the cytosolic 
calcium-regulated calpains, which are mainly involved in tissue 
injury, necrosis, and autolysis. The third pathway, and probably the 
most significant proteolytic contributor to muscle wasting in cancer 
cachexia is the ATP ubiquitin proteasome proteolytic pathway, whose 
preferred substrate is myosin heavy chain. Interestingly, the ubiquitin 
system is hyperactivated also in weight stable cancer patients. This 
evidence highlights the need to start the nutritional intervention 
as early as possible, since absence of clinical signs may not imply 
absence of metabolic derangements.
A number of mediators of muscle wasting have been identified. The 
pro-inflammatory cytokines TNF-α and IL-1 have been shown to 
activate the ubiquitin-proteasome system. Similar effects have been 
suggested to be mediated by the tumour-derived 24-kDa sulfated 
glycoprotein proteolysis-inducing factor (PIF), whose role in cancer 
cachexia has been recently questioned.15 In addition, there has been 
significant progress in identifying new signalling pathways that 
contribute to muscle atrophy that are potentially pertinent in cancer. 
Among others, these include the down-regulated insulin and insulin-
like growth factor pathways that lead to Akt inactivation and reversal 
of muscle hypertrophy; the angiotensin system that operates 
through the activation of caspases; the transforming growth factor-β 
family member myostatin; and the mediator of terminal muscle 
differentiation MyoD. Interestingly, most, if not all, of these emerging 
pathways seem to mediate their effects through the activation of the 
ubiquitin-proteasome system.14 
Carbohydrate metabolism in cancer patients. In the 1920s, Warburg 
demonstrated that tumours differ in glucose metabolism from normal 
tissues by exhibiting an enhanced glycolytic pathway. Under normal 
oxygen-rich conditions, tissues metabolise glucose to pyruvate, 
which then is completely oxidised to CO2 and H2O via the tricarboxylic 
acid (TCA) cycle and oxidative phosphorylation. Conversely, in 
states of low oxygen tension, as may occur in some solid tumours, 
cells can rely solely on anaerobic glycolysis, in which glucose is 
converted to pyruvate and then lactate in the cytosol to meet energy 
needs; this is known as the Pasteur effect. Many invasive cancer 
cells selectively metabolise glucose to lactic acid in the presence 
of oxygen, a phenomenon known as the Warburg effect. There are 
several defects in cell biochemistry that may facilitate the anaerobic 
glycolytic phenotype in cancer cells over the more efficient oxidative 
phosphorylation.16 The excess of lactate surrounding tumour cells 
is transported to the liver, where the carbon skeleton undergoes an 
energy-consuming gluconeogenic process to re-form glucose. It is 
important to underline that the creation of a futile Cori cycle can 
account for as much as a 300 kcal/day energy loss.17
Tumour-induced alterations in glucose metabolism include also 
insulin resistance, and 37% of all patients with cancer show glucose 
intolerance and abnormal insulin responses. Consistent evidence 
implicates the action of cytokines on glucose metabolism directly or 
by stimulation of glucoregulatory hormones.
Lipid metabolism in cancer patients. In cancer patients, an extensive 
depletion of adipose tissue is frequently observed. The loss of fat 
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stores cannot be explained by reduced appetite alone.17 Increased 
lipolysis appears to be a key factor underlying the loss of adipose 
tissue in cancer cachexia. Enhanced expression and activity of 
hormone-sensitive lipase (HSL), a rate-limiting enzyme of the 
lipolytic pathway, is thought to underlie the increase in lipolysis. 
In addition to increased lipolysis, there is a fall in lipoprotein lipase 
(LPL) activity.
Various factors produced by tumours, or by the host’s immune 
cells responding to the tumour, can alter lipid metabolism.18 Pro-
inflammatory cytokines such as TNF-α, IL-1 and IL-6 have been 
implicated in adipose atrophy in cachexia. Certain tumours produce 
circulating factors such as the 41 kDa zinc-α2-glycoprotein (ZAG). 
The biological functions of ZAG were largely unknown until a lipid-
mobilising factor (LMF), purified from the urine of cancer patients 
with cachexia, was shown to be identical to ZAG.
Energy metabolism in cancer patients. Coupling of energy intake 
with energy production is a mechanism to conserve energy when 
energy intake is low while disposing of excess ingested energy 
when energy intake is excessive. However, in cancer patients 
there is an uncoupling of the balance between energy production 
and energy intake in favour of increased energy production.17 One 
possible explanation for this increased energy expenditure is that 
the tumour-bearing host metabolism is energetically inefficient due 
to increased futile cycle activity. The recycling of lactate between 
the tumour and the host is certainly energetically inefficient. Pro-
inflammatory cytokines IL-6 and TNF-α have been implicated in 
stimulating gluconeogenesis and activating a futile cycle of glucose 
use and lactate formation in hepatocytes and myocytes, respectively.
Nonshivering thermogenesis takes place in brown adipose tissue 
(BAT) whereby energy uncoupled from oxidative phosphorylation 
is released as heat energy instead of fuelling ATP production. 
During cachexia, there is an increase in BAT thermogenesis. Brown 
adipocytes contain mitochondria that are characterised by the 
presence of uncoupling proteins 1,2,3 (UCP1, UCP2, UCP3). The 
UCP proteins are a family of mitochondrial membrane proteins that 
decrease the coupling of oxidative phosphorylation to ATP formation, 
culminating in the production of heat rather than ATP. Increased UCP-
mediated thermogenesis in BAT increases energy expenditure and 
may exacerbate cancer cachexia.
Cancer cachexia: a unifying hypothesis of its 
pathogenesis
For decades, the accepted model of the pathogenesis of cancer 
cachexia was based on the assumption that behavioural changes 
(i.e. anorexia) and metabolic alterations (i.e. muscle wasting, 
increased energy expenditure) were mediated by the derangement 
of different molecular pathways. Accumulating evidence now 
challenges this approach by suggesting that anorexia and wasting 
represent in part different phenotypes of common neurochemical/
metabolic alterations.12
Hypothalamic signalling and changes in energy expenditure. 
As previously described in detail, the inhibitory effects of pro-
inflammatory cytokines on fatty acid oxidation contribute to the 
dysregulation of the melanocortin system, thus leading to reduced 
energy intake. However, inhibition of fatty acid oxidation within 
hypothalamic neurons influences metabolism in peripheral tissues. 
The “malonyl-CoA signal” is rapidly transmitted to peripheral tissues 
by the sympathetic nervous system, increasing mitochondrial 
biogenesis, fatty acid oxidation and uncoupling protein-3 expression, 
and thus energy expenditure. Also, since mitochondria are among the 
main sources of reactive oxygen species production, it is postulated 
that this “brain–muscle axis” may contribute to increased oxidative 
stress, which in turn increases muscle protein degradation.
Hypothalamic signalling and muscle mass regulation. Experimental 
studies aimed at suppressing the activity of the central melanocortin 
system during cancer resulted in increased food intake, which was 
paralleled by amelioration of energy expenditure and improved lean 
body mass. The mechanisms by which MC4R antagonism in cancer 
models exerts its metabolic effects are still a matter of investigation. 
Recent data suggest that the improvement of basal metabolic rate is 
partly mediated by the normalisation of the expression of uncoupling 
proteins. Much less is known about the mechanisms leading to 
preserved body weight and lean body mass. In particular, it is yet to 
be determined whether central melanocortin antagonism influences 
the activity of the peripheral ATP-dependent ubiquitin-proteasome 
system. Nevertheless, the existence of a “brain-muscle axis” is likely, 
in which the brain not only regulates energy intake, but influences 
metabolic rate and the balance in muscles between anabolism and 
catabolism. The exact mechanisms of the interplay between central 
and peripheral pathways await better detailing, however it appears 
to involve the balance between inhibitory and stimulatory factors 
of the regulation of muscle mass, as recently demonstrated in an 
animal model of uraemic cachexia. In particular, the expression of 
myostatin, an important inhibitory factor of muscle mass accretion, is 
increased in the muscles of uraemic rats. In contrast, the expression 
of insulin-like growth factor-I, a factor promoting muscle accretion, 
is reduced. Interestingly, the injection of AgRP in the third ventricles 
of uraemic rats partially corrected these uraemia-induced changes, 
resulting in a gain of body mass.
Does clinical cancer cachexia match accumulating 
molecular evidence?
To strengthen the hypothesis that anorexia and wasting share similar 
pathogenic pathways, it would be important to verify whether they 
are clinically equivalent in the clinical practice. To this end, it is 
important to review the available definitions of cachexia and the 
clinical definition of cancer cachexia. Indeed, if the pathogenesis 
of cancer anorexia and tumour-associated tissue wasting is, at 
least in part, common, then it may be more appropriate to refer 
to the constellation of symptoms and signs leading to weight loss 
using a single term, i.e. cachexia, rather than anorexia-cachexia. 
Unfortunately, a widely accepted consensus on the definition of 
cancer cachexia does not exist yet. To promote the use of a common 
language among scientists and clinicians, ESPEN has recently 
endorsed the Washington definition which identifies cachexia as a 
complex metabolic syndrome associated to an underlying illness, and 
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characterised by loss of weight and muscle mass with or without the 
loss of fat mass.19 Although this definition identifies cancer patients 
at risk of poorer outcome, on the other hand, patients meeting the 
criteria of cancer cachexia are likely to be in an advanced stage 
of nutritional depletion, which may limit the benefit of nutritional 
intervention. Therefore, the identification of symptoms related to the 
early phases of cachexia, or pre-cachexia, may help in identifying 
the higher risk patients and may favor the prompt start of nutrition 
therapy. ESPEN has recently proposed that pre-cachexia could 
be diagnosed in the simultaneous presence of underlying chronic 
disease, unintentional weight loss < 5% of usual body weight during 
the last six months, chronic or recurrent systemic inflammatory 
response, and anorexia or anorexia-related symptoms.6
Although other symptoms are considered as complementary criteria 
for cachexia (i.e. anorexia, anaemia), it appears evident that the 
available definitions of cancer cachexia identify weight loss as 
the hallmark of this syndrome.19,6 Therefore, it could be assumed 
that in the absence of weight loss, patients cannot be defined as 
cachectic. But is this an approach that is clinically relevant? A critical 
answer to this questions is provided by the recent paper by Lasheen 
& Walsh.20 The authors studied the symptoms reported by patients 
with advanced cancer, in particular lung, colorectal, breast, pelvic 
and prostate cancer.20 Twenty-six percent of the patients did not 
complain of weight loss or anorexia. However, approximately 1/3 
of patients complained of anorexia, 10% reported significant and 
involuntary weight loss and 31% reported anorexia and weight 
loss. Therefore, according to the Washington definition, 41% of the 
cancer population studied met the definition of cancer cachexia. In 
clinical medicine, any definition and the attendant diagnostic criteria 
are valuable since they identify patients at higher risk of negative 
clinical outcome. Therefore, it could be assumed that the outcome 
of the cachectic patients (i.e. those with weight loss or weight loss 
and anorexia) should be different from that of the cancer patients 
with anorexia but no weight loss. In contrast, the survival of cancer 
patients with weight loss only, anorexia only, and weight loss and 
anorexia did not differ.20 These results suggest that cancer cachexia 
is a multifaceted syndrome in which anorexia and weight loss due 
to wasting are clinically relevant symptoms which are not mutually 
exclusive.
Therefore, it seems that molecular and clinical evidence indicates 
that cancer cachexia should be better defined as a complex clinical 
syndrome, which is clinically characterised by a varying combination 
of anorexia and tissue wasting.21
Conclusion
Accumulating evidence consistently reveals that the brain is key in 
mediating, influencing and determining not only human behaviour 
but a number of metabolic pathways in peripheral tissues as well. 
These results provide the molecular basis to evidence showing that 
transcendental meditation improves blood pressure and insulin 
resistance,22 and that willingness to take part in a clinical trial 
relates to a better prognosis.23 The fascinating unifying hypothesis 
of the pathogenesis of cancer cachexia, when corroborated by 
further evidence, will support the view that the brain and the central 
nervous system are key in controlling many, if not all, psychological 
and biological aspects of human life.
Not surprisingly for a genius, Michelangelo had already realised 
the key role of the brain in human life, revealing this concept in the 
“Creation of Adam” in the Sistine Chapel. Although a quick look at 
the fresco on the ceiling may not suggest the presence of any hidden 
message, a more accurate look will reveal that the angels and the 
robe around the body of God clearly form the shape of a sectioned 
brain. And God is in the centre of the brain. Michelangelo was a neo-
aristothelic and in the painting he wanted to state that the presence 
of God is testified by the “divinity” of our brain. After 500 years, we 
may now use the painting of Michelangelo to state that the more we 
will know about our brain, the more we will learn about the biology of 
life and the best strategy to prevent and treat diseases.
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